Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Ultrasound treatment for glaucoma
ISRCTN ISRCTN50904302
ClinicalTrials.gov identifier
Public title Ultrasound treatment for glaucoma
Scientific title A randomised controlled prospective study of the effect of topical application of ultrasound for glaucoma
Acronym TUG
Serial number at source 20091044
Study hypothesis Low frequency ultrasound applied external to the limbus of the eye may induce a similar cytokine release to that of laser applied to the trabecular meshwork of the eye and thereby lead to a decrease in intra-ocular pressure.
Ethics approval Western Institute Review Board approved on the 26th June 2009 (submission no.: e30817; study no.: 1109459; protocol ID: 20091044)
Study design Randomised controlled prospective study
Countries of recruitment United States of America
Disease/condition/study domain Open angle glaucoma
Participants - inclusion criteria 1. Pre-existing glaucoma or ocular hypertension
2. Aged above 18 years, all genders welcome
Participants - exclusion criteria Infants
Anticipated start date 20/08/2009
Anticipated end date 30/08/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 25
Interventions Low frequency ultrasound application externally to the area adjacent to the limbus of the eye. Control is the other eye, where glaucoma is essentially equal - a coin toss determines which is the treated eye. The treatment is one session of approximately 10 minutes. The follow-up is for six months.
Primary outcome measure(s) Intraocular pressure changes, measured at one day, one week, one month, two months, three months and six months.
Secondary outcome measure(s) Tolerability to the intervention, measured at one day, one week, one month, two months, three months and six months.
Sources of funding Eye Sonix (USA)
Trial website
Publications
Contact name Dr  Donald  Schwartz
  Address 2650 Elm Avenue #108
  City/town Long Beach
  Zip/Postcode 90806
  Country United States of America
  Email dschwartz@eyesonix.com
Sponsor Eye Sonix (USA)
  Address 2650 Elm Avenue #108
  City/town Long Beach
  Zip/Postcode 90806
  Country United States of America
  Email dschwartz@eyesonix.com
  Sponsor website: http://eyesonix.com/
Date applied 04/11/2009
Last edited 02/12/2009
Date ISRCTN assigned 02/12/2009
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central